基因疗法和其他新型治疗方法用于查洛特玛丽牙病
Chiara Pisciotta1, Davide Pareyson1
1Unit of Rare Neurological Diseases, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Neuromuscular disorders : NMD
|July 16, 2023
概括
开发新的治疗方法Charcot-Marie-Tooth病 (CMT) 侧重于基因沉默,基因疗法和针对各种途径的新型化合物来修改疾病,因为目前缺乏有效的药物选择.
科学领域:
- 神经学 神经学
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 查洛-玛丽-牙病 (CMT) 目前缺乏有效的药物治疗方法,管理依赖于支持性护理.
- 在CMT的主要挑战是开发疾病修饰疗法.
研究的目的:
- 审查目前和新兴的治疗策略,用于查尔科-玛丽-牙病.
- 突出针对CMT涉及的遗传和分子途径的新方法.
主要方法:
- 研究基因沉默技术 (ASO,siRNA,shRNA,miRNA,CRISPR-Cas9) 对于CMT1A中的PMP22过度表达.
- 探索衰退性CMT形式的基因疗法和新型基因插入 (例如NT3).
- 检查针对神经素,未折叠蛋白质反应,HDAC6,巨细胞,脂质代谢和离子通道 (Nav1.8,P2×7) 的化合物.
主要成果:
- 对于CMT1A,PXT3003正在临床试验的后期阶段.
- 基因疗法和特定途径化合物在临床前和早期临床研究中显示出有前途.
- 目前正在调查向代谢异常,如索尔比托尔积累 (SORD基因) 和糖脂类.
结论:
- 目前正在探索CMT的多种治疗途径,包括遗传和药理干预.
- 了解CMT病理生理学的进步正在推动针对性治疗的发展.
- 重点转向疾病修饰,而不是仅仅是症状管理.
相关概念视频
Gene Therapy
25.6K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.6K
Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
Parkinson's Disease: Treatment
302
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
302
Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Microorganisms in Medicine and Therapeutics
62
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
62
Cystic Fibrosis: Management
195
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
195


